Eidogen-Sertanty Licenses Target Informatics Platform to AstraZeneca
Eidogen-Sertanty, Inc., a San Diego-based computational drug discovery solutions provider, is pleased to announce that AstraZeneca Pharmaceuticals LP (NYSE:AZN) has licensed access to its Target Informatics Platform(TM). Under the agreement, scientists at AstraZeneca R&D Boston will access Eidogen-Sertanty’s Target Informatics Platform (TIP(TM)) and EVE(TM) Comparative Visualization software to assist drug discovery efforts within their cancer and anti-infective therapeutic programs. Financial terms were not disclosed.
TIP is the world’s first protein structure informatics system. Through the integration of protein structural data and ligand binding site analysis, TIP is designed to bridge the knowledge gap between the disciplines of bioinformatics and cheminformatics.
“We are very excited that AstraZeneca R&D Boston has selected TIP to assist their drug discovery efforts. We’re confident that TIP will help AstraZeneca scientists accelerate lead discovery programs across a wide variety of target families and therapeutic areas,” said Dr. Steve Muskal, CEO of Eidogen-Sertanty.
About AstraZeneca
AstraZeneca (NYSE:AZN) is a major international healthcare business engaged in the research, development, manufacture and marketing of prescription pharmaceuticals and the supply of healthcare services. It is one of the world’s leading pharmaceutical companies in the world with healthcare sales of over $21.4 billion and leading positions in sales of gastrointestinal, cardiovascular, respiratory, oncology and neuroscience products. In the United States, AstraZeneca is a $9.6 billion healthcare business with more than 12,000 employees. AstraZeneca is listed in the Dow Jones Sustainability Index (Global) as well as the FTSE4Good Index. For more information about AstraZeneca, please visit: www.astrazeneca-us.com .
About Eidogen-Sertanty, Inc.
Eidogen-Sertanty, formed in March 2005 from the merger of Eidogen and Sertanty, is a privately held company providing pioneering knowledge-driven discovery solutions to biotechnology and pharmaceutical organizations. Eidogen-Sertanty’s unique and powerful suite of software, databases and drug discovery services enable customers and collaborators to apply a knowledge-driven discovery approach to a variety of workflows and processes, including target selection and prioritization, library building and compound prioritization, and lead design and optimization. To find out more about Eidogen-Sertanty and their products and services, please visit www.eidogen-sertanty.com .
Eidogen-Sertanty, the Eidogen-Sertanty logo, DirectDesign and Target Informatics Platform are trademarks of Eidogen-Sertanty, Inc.
All other trademarks in this release are the property of their respective owners.
